Skip to main content

Table 1 Characteristics of E. coli ST131 isolates by fimH subtyping

From: Prevalence and characteristics of ST131 clone among unselected clinical Escherichia coli in a Chinese university hospital

Characteristics

 

ST131 subclones, number of isolates (%)

P a

Total

H30Rx

H30 non-Rx

H41

H41 vs H30 non -Rx

H41 vs H30-Rx

H30 Rx vs H30 non-Rx

N = 83 (%)

n = 13

n = 40

n = 30

   

PCR O type

 O25b

55(66.3%)

12(92.3%)

40(100%)

3(10.0%)

< 0.001

< 0.001

 

 O16

28(33.7%)

1(7.7%)

0

27(90.0%)

   

Antimicrobial resistance

 ATM

30(36.1%)

12(92.3%)

11(27.5%)

7(23.3%)

 

< 0.001

< 0.001

 CAZ

22(26.5%)

10(76.9%)

5(12.5%)

7(23.3%)

 

0.002

< 0.001

 CTX

59(71.1%)

12(92.3%)

28(70%)

19(63.3%)

   

 FEP

26(31.3%)

11(84.6%)

10(25.0%)

5(16.7%)

 

< 0.001

< 0.001

 TZP

1(1.2%)

0

0

1(3.3%)

   

 CIP

58(69.9%)

13(100%)

40(100%)

5(16.7%)

< 0.001

< 0.001

 

 LEV

58(69.9%)

13(100%)

40(100%)

5(16.7%)

< 0.001

< 0.001

 

 AMK

7(8.4%)

3(23.1%)

1(2.50%)

3(10.0%)

  

0.042

 SXT

56(67.5%)

10(76.9%)

24(60.0%)

22(73.3%)

   

bla CTX-M type

 CTX-M-14

37(44.6%)

0

22(55.0%)

15(50.0%)

 

0.001

< 0.001

 CTX-M-15

22(26.5%)

12(92.3%)

7(17.5%)

3(10.0%)

 

< 0.001

< 0.001

 CTX-M-14,15

2(2.40%)

0

2(5.0%)

0

   

 CTX-M-123

1(1.2%)

0

0

1(3.3%)

   

 No ESBLb

21(25.3%)

1(7.7%)

11(27.5%)

9(30.0%)

   

FQR genesc

 5 gyrA, parC and parE mutationsd

51(61.4%)

13(100%)

35(87.5%)

3(10.0%)

< 0.001

< 0.001

 

  aac(6′)-Ib-cr

14(16.9%)

10(76.9%)

0

4(13.3%)

0.012

< 0.001

< 0.001

  qnr

4(4.8%)

0

2(5.0%)

2(6.70%)

   

Adhesins

  papAH

22 (26.5%)

12(92.3%)

6 (15.0%)

4(13.3%)

 

< 0.001

< 0.001

  papC

23 (27.7%)

13(100%)

6 (15.0%)

4(13.3%)

 

< 0.001

< 0.001

  papEF

22 (26.5%)

12(92.3%)

7(17.5%)

3(10.0%)

 

< 0.001

< 0.001

  papG allele I

0

0

0

0

   

  papG allele II

21 (25.3%)

12(92.3%)

6 (15.0%)

3(10.0%)

 

< 0.001

< 0.001

  sfa/focDE

1 (1.2%)

0

1(2.50%)

0

   

  focG

0

0

0

0

   

  afa/draBC

7 (8.4%)

0

2(5.0%)

5(16.7%)

   

  fimH

82 (98.8%)

13(100%)

39(97.5%)

30(100%)

   

  gafD

0

0

0

0

   

  sfaS

7 (8.4%)

3(23.1%)

3(7.5%)

1(3.3%)

   

Toxins

  hlyA

14 (16.9%)

11(84.6%)

1(2.50%)

2(6.70%)

 

< 0.001

< 0.001

  cnf1

10 (12.0%)

8(61.5%)

1(2.50%)

1(3.3%)

 

0.002

< 0.001

  cdtB

0

0

0

0

   

  cvaC

3 (3.6%)

0

0

3(10.0%)

0.042

  

Siderophores

  fyuA

81 (97.6%)

13(100%)

38(95.0%)

30(100%)

   

  iutA

77 (92.8%)

13(100%)

38(95.0%)

26(86.7%)

   

Capsules

  kpsMT II

62 (74.7%)

9(69.2%)

33(82.5%)

20(66.7%)

   

  kpsMT III

0

0

0

0

   

  kpsMT K1

10 (12.0%)

2(15.4%)

5(12.5%)

3(10.0%)

   

  kpsMT K5

47 (56.6%)

11(84.6%)

29(72.5%)

7(23.3%)

< 0.001

0.001

 

Miscellaneous

  nfaE

0

0

0

0

   

  rfc

0

0

0

0

   

  malX

76 (91.6%)

13(100%)

37(92.5%)

26(86.7%)

   

  traT

73 (88.0%)

13(100%)

32(80.0%.)

28(93.3%)

   

 Virulence scorese

7

9

7

6

 

0.001

0.001

  1. a P values, by either χ2 or Fisher’s exact test or Mann-Whitney test, are shown where P < 0.05
  2. bESBL, CTX-M-type extended-spectrum-β-lactamase genes
  3. cFQR, fluoroquinolone resistance
  4. dGyrA S83 L, D87N, ParC S80I, E84V, and ParE I529L
  5. emedian number of virulence factors (range)